Pacira生物科學 PCRX 深 滬
已收盤 02-06 16:00:00 美东时间
21.00
+0.640
+3.14%
華盛通- 最 高21.07
- 今 開20.61
- 成交量 74.65万股
- 最 低 20.435
- 昨 收 20.36
- 總市值 8.63亿
- 52周最高 27.64
- 市盈率 靜 --
- 換手率 1.82%
- 52周最低 18.80
- 委 比 -53.52%
- 總股本 4110.00万
- 歷史最高 121.95
- 量 比 1.07
- 振 幅 3.12%
- 歷史最低 6.51
- 每 手 1
- 風險率 1.84%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Pacira BioSciences SVP Finance Lauren Riker Reports Disposal of Common Shares
Pacira BioSciences SVP Finance Lauren Riker Reports Disposal of Common Shares Lauren Riker, Senior Vice President, Finance of Pacira BioSciences Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below. Disclaimer: This news brief was created
02-04 07:24
Pacira BioSciences Appoints Samit Hirawat, M.D., to Board of Directors
Pacira BioSciences, Inc. announced the appointment of Samit Hirawat, M.D., to its Board of Directors, expanding the Board to 10 members. Hirawat, a veteran in clinical development with over 25 years of experience, previously served as Chief Medical Officer and Head of Global Drug Development at Bristol Myers Squibb. He brings expertise in advancing innovative therapies, aligning with Pacira’s mission to deliver non-opioid pain solutions. Pacira’s...
01-28 13:00
Pacira Announces Agreement with LG Chem to Make EXPAREL® Available in Select Asian-Pacific Markets
Pacira BioSciences has granted LG Chem exclusive rights to distribute EXPAREL in select Asian-Pacific markets, expanding access to non-opioid pain management solutions. The partnership aims to address the high demand for long-acting post-surgical pain control and aligns with Pacira's 5x30 strategy. LG Chem will handle regulatory approvals in South Korea and Thailand, while Pacira will manufacture the product. The agreement includes an upfront pay...
01-13 13:00
美股大行评级 | 瑞穗上调英伟达、谷歌、美光科技、SanDisk多家科技股目标价；中金首予诺和诺德"跑赢大市"评级，目标价73.5美元
今日重点评级关注：Needham：维持Cartesian Therapeutics"买入"评级，目标价从40美元升至42美元；Piper Sandler：维持Acrivon Therapeutics"超配"评级，目标价从6美元升至8美元
01-12 14:09
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) stock increased by 19.2% to $1...
01-09 20:05
What Analysts Are Saying About Pacira BioSciences Stock
5 analysts have expressed a variety of opinions on Pacira BioSciences (NASDAQ:P...
01-09 20:01
Needham Maintains Buy on Pacira BioSciences, Maintains $30 Price Target
Needham analyst Serge Belanger maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and maintains $30 price target.
01-09 17:51
Pacira drops after adjusting 2025 revenue below consensus
Pacira BioSciences (PCRX) is down ~10% in after-hours trading Thursday after revising downwards its expectation for 2025 total revenues. The company reported preliminary full-year revenues of $726.4M....
01-09 06:49
Pacira reports preliminary FY25 revenue of $726.4M
Pacira BioSciences (PCRX) on Thursday reported preliminary, unaudited total revenue of $726.4 million for the year ended December 31, 2025, compared with $701.0 million for the year ended December 31,...
01-09 05:23
Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues
Pacira BioSciences reported preliminary 2025 revenue of $726.4 million, up 3.6% from 2024, driven by 7% growth in EXPAREL volume. Fourth-quarter EXPAREL sales rose 7% to $155.8 million, offsetting shifts in vial mix and discounting. Full-year EXPAREL sales reached $575.1 million, a 6% volume increase. ZILRETTA sales were stable, while iovera° sales rose slightly. The company repurchased 2.0 million shares in Q4 at a cost of $50.0 million, with $1...
01-08 21:01
